feburic作用与功效
Feburic is also called febuxostat or febuxostat. Japan invested in the research and development of this drug in 1970. It is a xanthine oxidase (XO) inhibitor suitable for the long-term treatment of hyperuricemia with gout symptoms. However, this product is not recommended for the treatment of asymptomatic hyperuricemia.
Feburic was approved for marketing in the United States in 2009 for the treatment of gout patients. The recommended dose is 40 mg or 80 mg once a day. The recommended starting dose is 40 mg and should be administered without regard to food or antacids. No dose adjustment is required in patients with mild or moderate renal impairment or hepatic impairment.
Purine nucleotides in food are mainly oxidized into uric acid by xanthine oxidase in two steps. Febuxostat has a relatively direct effect and can directly inhibit the activity of xanthine oxidase and reduce the production of uric acid. feburic (febuxostat, febuxostat) requires long-term medication. It is recommended that nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine be administered at the same time when using this product to prevent gout attacks. It is recommended to take the medicine for at least 6 months to prevent acute attacks of gout.
Feburic functions and effects:
Judging from official clinical trials, the effective rate of feburic (febuxostat, febuxostat) in the general population is about 70%, which is much higher than allopurinol. And compared to placebo, there was a clear difference. Clinical trial data on more than 3,000 people show that feburic can effectively reduce uric acid in the blood to 360 μmol/L after taking the medicine for six months.
Compared with allopurine, feburic has a significant inhibitory effect on both oxidized and reduced XOR, and its effect of reducing uric acid is more powerful and lasting; feburic (febuxostat, febuxostat) is a non-purine XOR inhibitor with fewer side effects and can also be used in patients with moderate and severe liver and kidney dysfunction. The patient's medication is safer.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)